贝利单抗治疗活动性狼疮性肾炎在亚洲潜伏性肺结核青年患者中的疗效:1例报告。

IF 0.9 Q4 UROLOGY & NEPHROLOGY
Case Reports in Nephrology and Dialysis Pub Date : 2025-07-02 eCollection Date: 2025-01-01 DOI:10.1159/000547171
Xiaojun Li, Meijing Li, Rongkuan Li, Qin Yao, Jie Sheng
{"title":"贝利单抗治疗活动性狼疮性肾炎在亚洲潜伏性肺结核青年患者中的疗效:1例报告。","authors":"Xiaojun Li, Meijing Li, Rongkuan Li, Qin Yao, Jie Sheng","doi":"10.1159/000547171","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Managing active lupus nephritis (LN) in the presence of latent tuberculosis (TB) presents a significant treatment challenge. Traditional treatment with glucocorticoids combined with mycophenolic acid carries a high risk of triggering pulmonary TB infection in LN patients. In this report, we discuss a novel approach using belimumab in combination with rapidly tapering corticosteroids to treat a patient with active class IV and V LN and latent TB.</p><p><strong>Case presentation: </strong>A 24-year-old Chinese male was diagnosed with active class IV and V LN and latent TB. He underwent induction therapy with a combination of belimumab, rapidly tapering methylprednisolone and mycophenolate mofetil. After 18 months of belimumab therapy, the patient's blood albumin levels and kidney function normalized, with 24-h urinary protein levels stabilizing between 500 mg and 725 mg. Notably, there was no recurrence of TB.</p><p><strong>Conclusion: </strong>This case demonstrates that the combination of belimumab and rapid corticosteroid tapering effectively reduced the duration of high-dose glucocorticoid therapy, highlighting the efficacy and safety of belimumab in managing LN with latent TB.</p>","PeriodicalId":9599,"journal":{"name":"Case Reports in Nephrology and Dialysis","volume":"15 1","pages":"161-169"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334148/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Belimumab for Active Lupus Nephritis in a Young Asian Man with Latent Pulmonary Tuberculosis: A Case Report.\",\"authors\":\"Xiaojun Li, Meijing Li, Rongkuan Li, Qin Yao, Jie Sheng\",\"doi\":\"10.1159/000547171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Managing active lupus nephritis (LN) in the presence of latent tuberculosis (TB) presents a significant treatment challenge. Traditional treatment with glucocorticoids combined with mycophenolic acid carries a high risk of triggering pulmonary TB infection in LN patients. In this report, we discuss a novel approach using belimumab in combination with rapidly tapering corticosteroids to treat a patient with active class IV and V LN and latent TB.</p><p><strong>Case presentation: </strong>A 24-year-old Chinese male was diagnosed with active class IV and V LN and latent TB. He underwent induction therapy with a combination of belimumab, rapidly tapering methylprednisolone and mycophenolate mofetil. After 18 months of belimumab therapy, the patient's blood albumin levels and kidney function normalized, with 24-h urinary protein levels stabilizing between 500 mg and 725 mg. Notably, there was no recurrence of TB.</p><p><strong>Conclusion: </strong>This case demonstrates that the combination of belimumab and rapid corticosteroid tapering effectively reduced the duration of high-dose glucocorticoid therapy, highlighting the efficacy and safety of belimumab in managing LN with latent TB.</p>\",\"PeriodicalId\":9599,\"journal\":{\"name\":\"Case Reports in Nephrology and Dialysis\",\"volume\":\"15 1\",\"pages\":\"161-169\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334148/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Nephrology and Dialysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000547171\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Nephrology and Dialysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000547171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在潜伏性结核(TB)存在的情况下管理活动性狼疮性肾炎(LN)提出了一个重大的治疗挑战。传统的糖皮质激素联合霉酚酸治疗有引发LN患者肺结核感染的高风险。在本报告中,我们讨论了一种新的方法,使用贝利单抗联合快速减量皮质类固醇治疗活动性IV级和V级LN和潜伏性结核病患者。病例介绍:一名24岁的中国男性被诊断为活动性IV型和V型LN和潜伏性结核。他接受了贝利单抗、快速减量甲基强的松龙和霉酚酸酯联合诱导治疗。贝利姆单抗治疗18个月后,患者血白蛋白水平和肾功能恢复正常,24小时尿蛋白水平稳定在500 - 725 mg之间。值得注意的是,没有结核复发。结论:本病例表明,贝利单抗联合快速减量皮质激素有效缩短了高剂量糖皮质激素治疗的持续时间,突出了贝利单抗治疗LN合并潜伏性TB的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Efficacy of Belimumab for Active Lupus Nephritis in a Young Asian Man with Latent Pulmonary Tuberculosis: A Case Report.

Efficacy of Belimumab for Active Lupus Nephritis in a Young Asian Man with Latent Pulmonary Tuberculosis: A Case Report.

Efficacy of Belimumab for Active Lupus Nephritis in a Young Asian Man with Latent Pulmonary Tuberculosis: A Case Report.

Introduction: Managing active lupus nephritis (LN) in the presence of latent tuberculosis (TB) presents a significant treatment challenge. Traditional treatment with glucocorticoids combined with mycophenolic acid carries a high risk of triggering pulmonary TB infection in LN patients. In this report, we discuss a novel approach using belimumab in combination with rapidly tapering corticosteroids to treat a patient with active class IV and V LN and latent TB.

Case presentation: A 24-year-old Chinese male was diagnosed with active class IV and V LN and latent TB. He underwent induction therapy with a combination of belimumab, rapidly tapering methylprednisolone and mycophenolate mofetil. After 18 months of belimumab therapy, the patient's blood albumin levels and kidney function normalized, with 24-h urinary protein levels stabilizing between 500 mg and 725 mg. Notably, there was no recurrence of TB.

Conclusion: This case demonstrates that the combination of belimumab and rapid corticosteroid tapering effectively reduced the duration of high-dose glucocorticoid therapy, highlighting the efficacy and safety of belimumab in managing LN with latent TB.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
36
审稿时长
10 weeks
期刊介绍: This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of nephrology and dialysis, including genetic susceptibility, clinical presentation, diagnosis, treatment or prevention, toxicities of therapy, critical care, supportive care, quality-of-life and survival issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信